CMS releases quality data for public consumer sites

Laura Pedulli | | Health Exec | Economics

 

The Centers for Medicare & Medicaid Services (CMS) has released data on the quality of care by physician groups, accountable care organizations and hospitals on multiple consumer websites.

These data, available on sites Physician Compare, Hospital Compare and Data.Medicare.gov, include information on hospital value-based purchasing program 2015 payment adjustments; updated performance results on diabetes and cardiovascular care by some physician group practices and ACOs; and hospital performance results on hospital-acquired conditions.

“CMS is committed to providing useful and current quality performance data. The Compare sites empower consumers with information to help with healthcare decisions, encourage providers to strive for higher levels of quality, and drive overall health system improvement,” according to the agency.

Read the CMS blog.

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.